Bhp: Silodosin an Effective New Drug for BPH-Associated LUTS

research highlights

BPH Silodosin an effective new drug for BPH-associated luTS

α1-adrenoceptor antagonists are the first- luts while minimizing adverse effects. groups. neither silodosin nor tamsulosin line treatment for men with lower urinary silodosin, a new α1a-adrenoceptor showed superiority over each other in tract symptoms (luts) suggestive of antagonist that has high uroselectivity terms of efficacy. retrograde ejaculation bladder outlet obstruction (Boo) caused in experimental animals, has now been was reported by more patients in the by benign prostatic hyperplasia (BPH). studied for the first time in european men silodosin group (14.2%) compared to the However, the lack of selectivity of some with luts and presumed BPH. tamsulosin (2.1%) and placebo (1.1%) of these agents can cause reduced blood in a multicenter, international, placebo- groups. the frequency of headache, the pressure and cardiovascular adverse controlled and active-controlled clinical next most-common adverse event, did events. Drugs that selectively target study, men with luts (defined as an not differ significantly between the three

α1a-adrenoceptors—the predominant international Prostate symptom score groups.

α1-adrenoceptor subtype in the bladder [iPss] ≥13) and Boo (peak maximum the authors conclude that silodosin outflow tract—are thought to improve flow rate [Qmax] 4–15 ml/s) were randomly is a safe and effective treatment for assigned to receive silodosin 8 mg moderate-to-severe luts caused by BPH, (n = 381), tamsulosin 0.4 mg (n = 384) or and might be most beneficial in elderly placebo (n = 190) once daily for 12 weeks. patients in whom drug–drug interactions Patients were assessed with the iPss are more likely and cardiovascular adverse

questionnaire and measurement of Qmax, effects need to be avoided. systolic and diastolic blood pressure and heart rate at baseline and after 7, 14, 28, 56 Nick Warde and 84 days of treatment. Compared to placebo, both active Original article Chapple, C. R. et al. Silodosin therapy treatments were associated with for lower urinary tract symptoms in men with suspected significantly greater improvements benign prostatic hyperplasia: results of an international in total iPsss, iPsss for storage and randomized, double-blind, placebo- and active-controlled voiding, and quality of life. increases in clinical trial performed in Europe. Eur. Urol. doi:10.1016/ j.eururo.2010.10.046 © Yuri arcurs | Dreamstime © Yuri Qmax did not differ significantly between